Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies



Status:Recruiting
Conditions:Lung Cancer, Prostate Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:December 21, 2017
End Date:October 2, 2021
Contact:Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES

This is a Phase 1b/2, open label, multicenter, safety and clinical activity study of avelumab
in combination with chemotherapy as first-line treatment of adult patients with locally
advanced or metastatic solid tumors. Initially, avelumab will be evaluated in combination
with pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung
cancer (NSCLC) (Cohort A1) and in combination with gemcitabine and cisplatin in patients with
cisplatin-eligible urothelial (bladder) cancer (UC) (Cohort A2). As more information is
learned about other anti-cancer immunotherapy agents, in future portions of the study,
avelumab may be combined with chemotherapy and other anti-cancer immunotherapy agents in
patients with these same or different tumor types.

This is a Phase 1b/2, open label, multicenter, safety, clinical activity, pharmacokinetic
(PK), and pharmacodynamics (PD) study of avelumab in combination with chemotherapy with or
without other anti-cancer immunotherapies, as first-line treatment of adult patients with
locally advanced or metastatic solid tumors. Initially, avelumab will be evaluated in
combination with pemetrexed and carboplatin in patients with advanced non-squamous non-small
cell lung cancer (NSCLC) (Cohort A1) and with gemcitabine and cisplatin in patients with
cisplatin-eligible urothelial cancer (UC) (Cohort A2).

Given the growing preclinical and clinical indications that combinations of anti-cancer
immunotherapies potentially improve patient outcomes compared to results seen with single
agents, in portions of the study to be added in the future, avelumab will be evaluated in
combination with both standard-of-care chemotherapy and other anti-cancer immunotherapies in
patients with advanced malignancies. Each cohort in the study will consist of a Phase 1b
lead-in portion to evaluate safety and a Phase 2 cohort expansion to evaluate safety and
efficacy.

In the Phase 1b safety lead-in portion, up to 12 patients will be enrolled into each cohort
and evaluated for dose-limiting toxicities (DLT) during the first 2 cycles of treatment. If
investigational products administration in a cohort is deemed safe in the Phase 1b lead-in,
enrollment may be expanded into the Phase 2 cohort expansion. Up to approximately 40 patients
in each cohort (including those enrolled in the Phase 1b lead-in and those enrolled in the
Phase 2 cohort expansion) will be enrolled and treated with avelumab plus chemotherapy in the
initial portion of the study and, in future portions of the study, with avelumab plus
chemotherapy with or without other anti-cancer immunotherapies.

In the Phase 1b lead-in portions of NSCLC Cohort A1 and UC Cohort A2, avelumab is dosed at
800 mg fixed dose every 3 weeks. Under Protocol Amendment 4, avelumab is dosed at 1200 mg
fixed dose every 3 weeks in the Phase 1b lead-in portions of NSCLC Cohort A3 and in UC Cohort
A4, in combination with the same standard-of-care chemotherapy doublets used in Cohort A1 and
Cohort A2, respectively. For each tumor type, the study treatment combination with the
highest avelumab dose determined to be safe may be advanced into Phase 2 cohort expansion.

Inclusion Criteria:

1. Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
tumor that is not amenable for treatment with curative intent as follows:

- For all groups:

- Measurable disease by RECIST v1.1 with at least 1 measurable lesion, and
availability of tumor specimen 18 months or less old.

- No prior systemic treatment for unresectable locally advanced or metastatic
disease for the tumor type under study. If prior systemic chemotherapy treatment
was given in the adjuvant or neo-adjuvant setting or as part of radiotherapy
chemotherapy treatment, disease-free interval after stop of systemic treatment
must be more than 6 months for non-squamous NSCLC and more than 12 months for UC;

- Cohort A1 and Cohort A3: Non-squamous NSCLC, with no activating EGFR mutations,
ALK or ROS1 translocations/rearrangements. If monotherapy pembrolizumab is
available as a standard of care treatment option, patients must have a tumor
proportion score (TPS) <50% for PD L1 (via the 22C3 pharmDx or the Ventana
(SP263) PD L1 IHC assay).

- Cohort A2 and Cohort A4: Transitional cell carcinoma of the urothelium including
the bladder, urethra, renal pelvis, and ureter.

2. ECOG performance status 0 or 1

3. Estimated life expectancy of at least 90 days

4. Adequate bone marrow, renal, and liver function

5. Negative serum pregnancy test at screening

6. Signed and dated informed consent

Exclusion Criteria:

1. Prior immunotherapy with any antibody or drug specifically targeting T cell
co-stimulation or immune checkpoint pathways.

2. Patients with known symptomatic central nervous system metastases requiring steroids.

3. Diagnosis of other malignancy within 2 years prior to enrollment except adequately
treated basal cell or squamous cell skin cancer, or carcinoma in situ of the bladder,
breast, or cervix, or low grade (Gleason ≤6) prostate cancer

4. Use of immunosuppressive medication at the time of enrollment

5. Active or prior autoimmune disease that might deteriorate when receiving an
immuno-stimulatory agent.

6. Prior organ transplantation including allogenic stem cell transplantation

7. Active infection requiring systemic therapy

8. Known history of HIV or AIDS

9. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening

10. Administration of live vaccine within 4 weeks prior to study entry

11. Known prior severe hypersensitivity to the investigational products or any component
in their formulations,

12. Known prior severe hypersensitivity to platinum-related compounds for all cohorts, to
pemetrexed for patients enrolled in Cohort A1 and Cohort A3, and to gemcitabine for
patients enrolled in Cohort A2 and Cohort A4

13. Persisting toxicity related to prior therapy (NCI CTCAE v4.03 Grade > 1)

14. Known history of colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.

15. Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade 2 or prolongation of the QTcF
interval to >480 msec.

16. Clinically significant (ie, active) cardiovascular disease: cerebral vascular
accident/stroke (<6 months prior to enrollment), myocardial infarction (< 6 months
prior to enrollment), unstable angina, congestive heart failure, or serious cardiac
arrhythmia requiring medication.

17. Major surgery ≤28 days or major radiation therapy ≤14 days prior to enrollment.

18. Participation in other studies involving investigational drug(s) within 28 days prior
to study entry.

19. Concurrent treatment with a prohibited medication.

20. Other acute or chronic medical or psychiatric condition

21. Pregnant female patients; breastfeeding female patients; fertile male patients and
female patients of childbearing potential who are unwilling or unable to use at least
1 highly effective method of contraception as outlined in this protocol for the
duration of the study and for at least 90 days after the last dose of chemotherapy
(for male and female patients) or at least 30 days after the last dose of avelumab
(for female patients), whichever is longer.
We found this trial at
16
sites
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
Danbury, Connecticut 06810
?
mi
from
Danbury, CT
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Los Angeles, California 90033
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90033
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Newport Beach, California 92658
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Norwalk, Connecticut 06856
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
3 Edmund D. Pellegrino Road
Stony Brook, New York 11794
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Stony Brook, New York 11794
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials